The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in PraderWilli syndrome: A systematic review
***Although these products are safe, they are contraindicated for the following patients: Thyroid cancer, gallbladder disease, pancreatitis, Endocrine disorders, pregnancy
Tier 1: Pure GLP-1, injectable, FDA-approved Exenatide (Byetta, Bydureon) Liraglutide (Victoza, Saxenda) Lixisenatide (Adlyxin) Dulaglutide (Trulicity) Semaglutide (Ozempic, Wegovy) Efpeglenatide (Eperzan) Tier 2: Pure GLP-1, oral, FDA-approved Semaglutide (Rybelsus) Orforglipron (Orfoglip) Tier 3: Dual or triple agonist, FDA-approved Tirzepatide (Mounjaro, Zepbound) Retatrutide (Retara) Tier 4: Compounded (not FDA-approved) Compounded semaglutide Compounded tirzepatide Compounded semaglutide + B12 Compounded tirzepatide + B12 The tier system reflects regulatory status, not efficacy
Drug Interactions: Do Antibiotics Affect Semaglutide's Efficacy
Understanding the Safety of Glutathione Supplementation for Diabetics Research Insights Recent studies have explored the effects of glutathione supplementation in individuals with diabetes
Tirzepatide, a medication shown to be highly effective for both blood sugar control and weight loss in individuals with diabetes, obesity, or who are overweight